RESUMO
We identified small-molecule dimer disruptors that inhibit an essential dimeric protease of human Kaposi's sarcoma-associated herpesvirus (KSHV) by screening an alpha-helical mimetic library. Next, we synthesized a second generation of low-micromolar inhibitors with improved potency and solubility. Complementary methods including size exclusion chromatography and 1H-13C HSQC titration using selectively labeled 13C-Met samples revealed that monomeric protease is enriched in the presence of inhibitor. 1H-15N HSQC titration studies mapped the inhibitor binding site to the dimer interface, and mutagenesis studies targeting this region were consistent with a mechanism where inhibitor binding prevents dimerization through the conformational selection of a dynamic intermediate. These results validate the interface of herpesvirus proteases and other similar oligomeric interactions as suitable targets for the development of small-molecule inhibitors.
Assuntos
Herpesvirus Humano 8/efeitos dos fármacos , Herpesvirus Humano 8/enzimologia , Inibidores de Proteases/farmacologia , Multimerização Proteica/efeitos dos fármacos , Bibliotecas de Moléculas Pequenas/farmacologia , Sítios de Ligação , Herpesvirus Humano 8/genética , Humanos , Modelos Moleculares , Mutação Puntual , Inibidores de Proteases/síntese química , Inibidores de Proteases/química , Conformação Proteica , Bibliotecas de Moléculas Pequenas/síntese química , Bibliotecas de Moléculas Pequenas/química , Especificidade por SubstratoRESUMO
Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), the most common cancer in AIDS patients. All herpesviruses express a conserved dimeric serine protease that is required for generating infectious virions and is therefore of pharmaceutical interest. Given the past challenges of developing drug-like active-site inhibitors to this class of proteases, small-molecules targeting allosteric sites are of great value. In light of evidence supporting a strong structural linkage between the dimer interface and the protease active site, we have focused our efforts on the dimer interface for identifying dimer disrupting inhibitors. Here, we describe a high throughput screening approach for identifying small molecule dimerization inhibitors of KSHV protease. The helical mimetic, small molecule library used, as well as general strategies for selecting compound libraries for this application will also be discussed. This methodology can be applicable to other systems where an alpha helical moiety plays a dominant role at the interaction site of interest, and in vitro assays to monitor function are in place.
Assuntos
Avaliação Pré-Clínica de Medicamentos/métodos , Herpesvirus Humano 8/enzimologia , Serina Proteases/metabolismo , Inibidores de Serina Proteinase/química , Inibidores de Serina Proteinase/farmacologia , Dimerização , Serina Proteases/químicaRESUMO
ATP-dependent nucleosome-remodeling motors use the energy of ATP to alter the accessibility of the underlying DNA. Understanding how these motors alter nucleosome structure can be aided by following changes in histone-DNA contacts in real time. Here, we describe a fluorescence resonance energy transfer-based approach that enables visualization of such changes.
Assuntos
Transferência Ressonante de Energia de Fluorescência/métodos , Conformação de Ácido Nucleico , Nucleossomos/química , Nucleossomos/metabolismo , Montagem e Desmontagem da Cromatina , DNA/metabolismo , Corantes Fluorescentes/metabolismo , Histonas/isolamento & purificação , Histonas/metabolismo , Humanos , Cinética , Modelos Biológicos , Reação em Cadeia da Polimerase , Coloração e Rotulagem , Estatística como AssuntoRESUMO
All members of the human herpesvirus protease (HHV Pr) family are active as weakly associating dimers but inactive as monomers. A small-molecule allosteric inhibitor of Kaposi's sarcoma-associated herpesvirus protease (KSHV Pr) traps the enzyme in an inactive monomeric state where the C-terminal helices are unfolded and the hydrophobic dimer interface is exposed. NMR titration studies demonstrate that the inhibitor binds to KSHV Pr monomers with low micromolar affinity. A 2.0-Å-resolution X-ray crystal structure of a C-terminal truncated KSHV Pr-inhibitor complex locates the binding pocket at the dimer interface and displays significant conformational perturbations at the active site, 15 Å from the allosteric site. NMR and CD data suggest that the small molecule inhibits human cytomegalovirus protease via a similar mechanism. As all HHV Prs are functionally and structurally homologous, the inhibitor represents a class of compounds that may be developed into broad-spectrum therapeutics that allosterically regulate enzymatic activity by disrupting protein-protein interactions.